7/107 sources · 6 publishersUpdated Oct 8, 18:32 UTC
Sanofi pays $1 billion upfront to expand partnership with Regeneron for new immunology antibodies
Sanofi will give Regeneron $1 billion up front and may pay up to $7 billion in milestones to co‑develop and co‑commercialise four next‑generation antibodies targeting IL‑13, IL‑4 and related pathways. Regeneron will lead research while Sanofi will handle worldwide sales. The agreement also settles a prior dispute over Dupixent commercial data.
Why it matters
The company says the deal eases investor concerns about Dupixent patent expirations by creating a pipeline of potential successors. Analysts at Leerink Partners note the collaboration could help both firms launch new products before biosimilars enter the market.
Key facts
- 1Sanofi will pay $1 billion upfront to Regeneron. marketscreener.com
- 2Milestones could add up to $7 billion for Regeneron. marketscreener.com
- 3Four new long‑acting antibodies will be co‑developed and co‑commercialised. pharmaceutical-technology.com
- 4Regeneron will lead R&D; Sanofi will lead global commercialization. pharmaceutical-technology.com
- 5The companies settled a prior litigation over Dupixent sales information. pharmaceutical-technology.com
- 6Sanofi’s shares rose 2.7% after the announcement. pharmaceutical-technology.com
Summary written by AlphAI from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.